HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Budget Request Leans On Proposed User Fees For Drug Safety Funding

This article was originally published in The Tan Sheet

Executive Summary

Funding for FDA's drug safety programs would receive a boost from user fees under President Bush's fiscal 2009 budget request, allowing the Center for Drug Evaluation and Research to hire an additional 283 full-time staff, for a total of 2,820

You may also be interested in...



Bush’s Addition To 2009 Request Undermines Immediate FDA Needs – Specter

Senate Appropriations Committee member Arlen Specter says President Bush's request to add $275 million to FDA's fiscal 2009 budget request undermines efforts to increase current funding

Dingell Import Safety Bill Includes User Fees To Fund Foreign Inspections

Legislation introduced by House Energy and Commerce Committee members Sept. 20 to improve food and drug import safety would authorize user fees to be directed at hiring more FDA inspectors and other officials for import analysis in the U.S. and abroad

Durbin Amendment Will Not Supersede AER Bill, Affect Supplements – Hatch

An amendment to the "Food and Drug Administration Revitalization Act" establishing an adulterated food registry does not apply to dietary supplements, Sen. Orrin Hatch, R-Utah, stressed in a statement before the Senate May 3

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel